Name | Number of supported studies | Average coverage | |
---|---|---|---|
enterocyte | 6 studies | 27% ± 9% | |
hepatocyte | 5 studies | 59% ± 23% | |
epithelial cell of proximal tubule | 5 studies | 20% ± 4% | |
hepatic stellate cell | 3 studies | 49% ± 17% |
Insufficient scRNA-seq data for expression of NR1H4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
liver | 100% | 4776.62 | 226 / 226 | 97% | 49.28 | 395 / 406 |
kidney | 100% | 1524.79 | 89 / 89 | 89% | 37.73 | 806 / 901 |
adrenal gland | 100% | 2346.53 | 258 / 258 | 32% | 11.73 | 74 / 230 |
pancreas | 88% | 178.31 | 288 / 328 | 29% | 3.73 | 51 / 178 |
ovary | 97% | 965.79 | 174 / 180 | 1% | 0.08 | 3 / 430 |
bladder | 57% | 138.76 | 12 / 21 | 9% | 1.28 | 44 / 504 |
intestine | 52% | 871.93 | 498 / 966 | 6% | 0.74 | 31 / 527 |
prostate | 13% | 12.13 | 32 / 245 | 1% | 0.04 | 3 / 502 |
esophagus | 1% | 0.82 | 9 / 1445 | 8% | 1.35 | 15 / 183 |
lung | 4% | 4.19 | 26 / 578 | 4% | 0.44 | 42 / 1155 |
stomach | 4% | 3.91 | 16 / 359 | 3% | 0.45 | 10 / 286 |
uterus | 2% | 2.60 | 4 / 170 | 3% | 0.68 | 14 / 459 |
heart | 4% | 3.26 | 35 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 3% | 5.99 | 26 / 929 | 0% | 0 | 0 / 0 |
brain | 1% | 0.83 | 23 / 2642 | 1% | 0.11 | 8 / 705 |
blood vessel | 2% | 1.98 | 24 / 1335 | 0% | 0 | 0 / 0 |
breast | 1% | 1.04 | 3 / 459 | 0% | 0.09 | 4 / 1118 |
spleen | 1% | 4.20 | 2 / 241 | 0% | 0 | 0 / 0 |
skin | 0% | 0.19 | 2 / 1809 | 0% | 0.04 | 2 / 472 |
adipose | 0% | 0.46 | 4 / 1204 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 80 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 29 |
muscle | 0% | 0 | 0 / 803 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
thymus | 0% | 0 | 0 / 653 | 0% | 0 | 0 / 605 |
tonsil | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 45 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0071417 | Biological process | cellular response to organonitrogen compound |
GO_0090181 | Biological process | regulation of cholesterol metabolic process |
GO_0010903 | Biological process | negative regulation of very-low-density lipoprotein particle remodeling |
GO_1904179 | Biological process | positive regulation of adipose tissue development |
GO_0006366 | Biological process | transcription by RNA polymerase II |
GO_0007043 | Biological process | cell-cell junction assembly |
GO_0006954 | Biological process | inflammatory response |
GO_0055089 | Biological process | fatty acid homeostasis |
GO_0008206 | Biological process | bile acid metabolic process |
GO_0007219 | Biological process | Notch signaling pathway |
GO_0032692 | Biological process | negative regulation of interleukin-1 production |
GO_0032703 | Biological process | negative regulation of interleukin-2 production |
GO_0032715 | Biological process | negative regulation of interleukin-6 production |
GO_0045087 | Biological process | innate immune response |
GO_0006357 | Biological process | regulation of transcription by RNA polymerase II |
GO_0038185 | Biological process | nuclear receptor-mediated bile acid signaling pathway |
GO_0071638 | Biological process | negative regulation of monocyte chemotactic protein-1 production |
GO_1903413 | Biological process | cellular response to bile acid |
GO_0030522 | Biological process | intracellular receptor signaling pathway |
GO_2000213 | Biological process | positive regulation of glutamate metabolic process |
GO_0000122 | Biological process | negative regulation of transcription by RNA polymerase II |
GO_0001678 | Biological process | intracellular glucose homeostasis |
GO_2001250 | Biological process | positive regulation of ammonia assimilation cycle |
GO_0010988 | Biological process | regulation of low-density lipoprotein particle clearance |
GO_0042632 | Biological process | cholesterol homeostasis |
GO_0035774 | Biological process | positive regulation of insulin secretion involved in cellular response to glucose stimulus |
GO_0038183 | Biological process | bile acid signaling pathway |
GO_0050728 | Biological process | negative regulation of inflammatory response |
GO_0043066 | Biological process | negative regulation of apoptotic process |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0061178 | Biological process | regulation of insulin secretion involved in cellular response to glucose stimulus |
GO_0030154 | Biological process | cell differentiation |
GO_1905695 | Biological process | positive regulation of phosphatidic acid biosynthetic process |
GO_0042742 | Biological process | defense response to bacterium |
GO_0046628 | Biological process | positive regulation of insulin receptor signaling pathway |
GO_0001080 | Biological process | nitrogen catabolite activation of transcription from RNA polymerase II promoter |
GO_0071222 | Biological process | cellular response to lipopolysaccharide |
GO_0032689 | Biological process | negative regulation of type II interferon production |
GO_0070857 | Biological process | regulation of bile acid biosynthetic process |
GO_0032720 | Biological process | negative regulation of tumor necrosis factor production |
GO_0010804 | Biological process | negative regulation of tumor necrosis factor-mediated signaling pathway |
GO_0043124 | Biological process | negative regulation of canonical NF-kappaB signal transduction |
GO_0034255 | Biological process | regulation of urea metabolic process |
GO_0032740 | Biological process | positive regulation of interleukin-17 production |
GO_0035356 | Biological process | intracellular triglyceride homeostasis |
GO_0034162 | Biological process | toll-like receptor 9 signaling pathway |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0071398 | Biological process | cellular response to fatty acid |
GO_0043235 | Cellular component | receptor complex |
GO_0000791 | Cellular component | euchromatin |
GO_0005654 | Cellular component | nucleoplasm |
GO_0090575 | Cellular component | RNA polymerase II transcription regulator complex |
GO_0000785 | Cellular component | chromatin |
GO_0005634 | Cellular component | nucleus |
GO_0000978 | Molecular function | RNA polymerase II cis-regulatory region sequence-specific DNA binding |
GO_0016922 | Molecular function | nuclear receptor binding |
GO_0001228 | Molecular function | DNA-binding transcription activator activity, RNA polymerase II-specific |
GO_0000977 | Molecular function | RNA polymerase II transcription regulatory region sequence-specific DNA binding |
GO_0000981 | Molecular function | DNA-binding transcription factor activity, RNA polymerase II-specific |
GO_0043565 | Molecular function | sequence-specific DNA binding |
GO_1902122 | Molecular function | chenodeoxycholic acid binding |
GO_0004879 | Molecular function | nuclear receptor activity |
GO_0001221 | Molecular function | transcription coregulator binding |
GO_0032052 | Molecular function | bile acid binding |
GO_0046965 | Molecular function | nuclear retinoid X receptor binding |
GO_0003700 | Molecular function | DNA-binding transcription factor activity |
GO_0008270 | Molecular function | zinc ion binding |
GO_0005515 | Molecular function | protein binding |
Gene name | NR1H4 |
Protein name | Farnesoid X nuclear receptor Nuclear receptor subfamily 1 group H member 4 Bile acid receptor (Farnesoid X-activated receptor) (Farnesol receptor HRR-1) (Nuclear receptor subfamily 1 group H member 4) (Retinoid X receptor-interacting protein 14) (RXR-interacting protein 14) Farnesoid X receptor (Nuclear receptor subfamily 1, group H, member 4, isoform CRA_a) NR1H4 protein |
Synonyms | RIP14 hCG_20893 BAR HRR1 FXR |
Description | FUNCTION: Ligand-activated transcription factor. Receptor for bile acids (BAs) such as chenodeoxycholic acid (CDCA), lithocholic acid, deoxycholic acid (DCA) and allocholic acid (ACA). Plays a essential role in BA homeostasis through the regulation of genes involved in BA synthesis, conjugation and enterohepatic circulation. Also regulates lipid and glucose homeostasis and is involved innate immune response . The FXR-RXR heterodimer binds predominantly to farnesoid X receptor response elements (FXREs) containing two inverted repeats of the consensus sequence 5'-AGGTCA-3' in which the monomers are spaced by 1 nucleotide (IR-1) but also to tandem repeat DR1 sites with lower affinity, and can be activated by either FXR or RXR-specific ligands. It is proposed that monomeric nuclear receptors such as NR5A2/LRH-1 bound to coregulatory nuclear responsive element (NRE) halfsites located in close proximity to FXREs modulate transcriptional activity (By similarity). In the liver activates transcription of the corepressor NR0B2 thereby indirectly inhibiting CYP7A1 and CYP8B1 (involved in BA synthesis) implicating at least in part histone demethylase KDM1A resulting in epigenomic repression, and SLC10A1/NTCP (involved in hepatic uptake of conjugated BAs). Activates transcription of the repressor MAFG (involved in regulation of BA synthesis) (By similarity). Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine) . Activates transcription of SLC27A5/BACS and BAAT (involved in BA conjugation), ABCB11/BSEP (involved in bile salt export) by directly recruiting histone methyltransferase CARM1, and ABCC2/MRP2 (involved in secretion of conjugated BAs) and ABCB4 (involved in secretion of phosphatidylcholine in the small intestine) . In the intestine activates FGF19 expression and secretion leading to hepatic CYP7A1 repression . The function also involves the coordinated induction of hepatic KLB/beta-klotho expression (By similarity). Regulates transcription of liver UGT2B4 and SULT2A1 involved in BA detoxification; binding to the UGT2B4 promoter seems to imply a monomeric transactivation independent of RXRA . Modulates lipid homeostasis by activating liver NR0B2/SHP-mediated repression of SREBF1 (involved in de novo lipogenesis), expression of PLTP (involved in HDL formation), SCARB1 (involved in HDL hepatic uptake), APOE, APOC1, APOC4, PPARA (involved in beta-oxidation of fatty acids), VLDLR and SDC1 (involved in the hepatic uptake of LDL and IDL remnants), and inhibiting expression of MTTP (involved in VLDL assembly . Increases expression of APOC2 (promoting lipoprotein lipase activity implicated in triglyceride clearance) . Transrepresses APOA1 involving a monomeric competition with NR2A1 for binding to a DR1 element . Also reduces triglyceride clearance by inhibiting expression of ANGPTL3 and APOC3 (both involved in inhibition of lipoprotein lipase) . Involved in glucose homeostasis by modulating hepatic gluconeogenesis through activation of NR0B2/SHP-mediated repression of respective genes. Modulates glycogen synthesis (inducing phosphorylation of glycogen synthase kinase-3) (By similarity). Modulates glucose-stimulated insulin secretion and is involved in insulin resistance . Involved in intestinal innate immunity. Plays a role in protecting the distal small intestine against bacterial overgrowth and preservation of the epithelial barrier (By similarity). Down-regulates inflammatory cytokine expression in several types of immune cells including macrophages and mononuclear cells . Mediates trans-repression of TLR4-induced cytokine expression; the function seems to require its sumoylation and prevents N-CoR nuclear receptor corepressor clearance from target genes such as IL1B and NOS2 . Involved in the TLR9-mediated protective mechanism in intestinal inflammation. Plays an anti-inflammatory role in liver inflammation; proposed to inhibit pro-inflammatory (but not antiapoptotic) NF-kappa-B signaling) (By similarity). .; FUNCTION: [Isoform 1]: Promotes transcriptional activation of target genes NR0B2/SHP (inducible by unconjugated CDCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; low activity for ABCB11/BSEP (inducible by unconjugated CDCA, DCA and ACA); not inducible by taurine- and glycine-amidated CDCA. .; FUNCTION: [Isoform 2]: Promotes transcriptional activation of target genes ABCB11/BSEP (inducible by unconjugated CDCA, DCA and ACA), NR0B2/SHP (inducible by unconjugated CDCA DCA and ACA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; not inducible by taurine- and glycine-amidated CDCA. .; FUNCTION: [Isoform 3]: Promotes transcriptional activation of target genes NR0B2/SHP (inducible by unconjugated CDCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and IBAP; low activity for ABCB11/BSEP (inducible by unconjugated CDCA, DCA and ACA); not inducible by taurine- and glycine-amidated CDCA. .; FUNCTION: [Isoform 4]: Promotes transcriptional activation of target genes ABCB11/BSEP (inducible by unconjugated CDCA, ACA and DCA), NR0B2/SHP (inducible by unconjugated CDCA, ACA and DCA), SLC51B/OSTB (inducible by unconjugated CDCA and DCA) and FABP6/IBAP; most efficient isoform compared to isoforms 1 to 3; not inducible by taurine- and glycine-amidated CDCA. . |
Accessions | F8W1M1 ENST00000548621.2 ENST00000549996.5 [Q96RI1-5] ENST00000392986.8 [Q96RI1-1] ENST00000551379.5 [Q96RI1-3] B6ZGS9 H0YHD5 ENST00000321046.9 G8JLB0 ENST00000548884.5 [Q96RI1-2] ENST00000188403.7 [Q96RI1-4] F1DAL1 ENST00000649582.1 ENST00000551184.1 Q96RI1 F8W656 Q6IPQ7 ENST00000546380.1 ENST00000648861.1 [Q96RI1-1] |